Mineralocorticoid Receptor Blockade in Chronic Kidney Disease

被引：20
|
作者：
Volk, Matthew J. [2 ]
Bomback, Andrew S. [3 ]
Klemmer, Philip J. [1 ]
机构：
[1] Univ N Carolina, UNC Kidney Ctr, Chapel Hill, NC 27514 USA
[2] Univ N Carolina, Dept Med, Div Nephrol & Hypertens, Chapel Hill, NC 27514 USA
[3] Columbia Univ, Dept Med, Div Nephrol, Coll Phys & Surg, New York, NY USA
来源：
CURRENT HYPERTENSION REPORTS | 2011年 / 13卷 / 04期
关键词：
Aldosterone; Aldosterone breakthrough; Mineralocorticoid blockade; Chronic kidney disease; CKD; Extracellular volume; Bioimpedance; Tissue inflammation; Hyperkalemia; Hypertension; ANGIOTENSIN-ALDOSTERONE SYSTEM; METABOLIC SYNDROME; PERITONEAL-DIALYSIS; BLOOD-PRESSURE; RESISTANT HYPERTENSION; ALDACTONE THERAPY; DIETARY-SODIUM; RENAL-DISEASE; UP-REGULATION; SLEEP-APNEA;
D O I：
10.1007/s11906-011-0202-2
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
Aldosterone antagonists have been highly successful in treating congestive heart failure and resistant hypertension. Until recently, therapies targeting the mineralocorticoid receptor in chronic kidney disease (CKD) have received little attention, largely because of the risk of hyperkalemia and the incorrect assumption that traditional therapy with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or both consistently reduces activity of the renin-angiotensin system in all patients. Control of extracellular volume and low-dose mineralocorticoid receptor blocker therapy may offer additional antihypertensive and anti-inflammatory benefits in select CKD populations.
引用
收藏
页码：282 / 288
页数：7
相关论文
共 50 条
  • [1] Mineralocorticoid Receptor Blockade in Chronic Kidney Disease
    Matthew J. Volk
    Andrew S. Bomback
    Philip J. Klemmer
    [J]. Current Hypertension Reports, 2011, 13 : 282 - 288
  • [2] Mineralocorticoid Receptor Blockade in Chronic Kidney Disease
    Bomback, Andrew S.
    Klemmer, Philip J.
    [J]. BLOOD PURIFICATION, 2012, 33 (1-3) : 119 - 124
  • [3] Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease
    Bertocchio, Jean-Philippe
    Warnock, David G.
    Jaisser, Frederic
    [J]. KIDNEY INTERNATIONAL, 2011, 79 (10) : 1051 - 1060
  • [4] The mineralocorticoid receptor in chronic kidney disease
    Barrera-Chimal, Jonatan
    Jaisser, Frederic
    Anders, Hans-Joachim
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (13) : 3152 - 3164
  • [5] Mineralocorticoid receptor blockade-a novel approach to fight hyperkalaemia in chronic kidney disease
    Ritz, E.
    Pitt, B.
    [J]. CLINICAL KIDNEY JOURNAL, 2013, 6 (05): : 464 - 468
  • [6] Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease
    Georgianos, Panagiotis I.
    Agarwal, Rajiv
    [J]. KIDNEY INTERNATIONAL REPORTS, 2021, 6 (09): : 2281 - 2291
  • [7] Mineralocorticoid Receptor Blockers and Chronic Kidney Disease
    Jain, Gaurav
    Campbell, Ruth C.
    Warnock, David G.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (10): : 1685 - 1691
  • [8] MINERALOCORTICOID RECEPTOR ANTAGONISM IN CHRONIC KIDNEY DISEASE
    Gillis, Keith
    Lees, Jennifer
    Jardine, Alan
    Traynor, Jamie
    Mark, Patrick
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 468 - 469
  • [9] Mineralocorticoid receptor antagonists in patients with chronic kidney disease
    Cosimato, Cosimo
    Agoritsas, Thomas
    Mavrakanas, Thomas A.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2021, 219
  • [10] Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms
    Shavit, Linda
    Lifschitz, Meyer D.
    Epstein, Murray
    [J]. KIDNEY INTERNATIONAL, 2012, 81 (10) : 955 - 968
12345